Core Viewpoint - Key takeaway is that Koyuan Pharmaceutical (301281) anticipates a significant decline in net profit for 2025, projecting a range of 27.2 million to 39.3 million yuan, representing a year-on-year decrease of 35% to 55% [1] Group 1: Financial Performance - The company expects a net profit attributable to shareholders of 27.2 million to 39.3 million yuan for 2025, which is a decrease of 35% to 55% compared to the previous year [1] - The anticipated decline in profit is attributed to increased sales expenses due to intensified efforts in developing the formulation market [1] Group 2: Cost Factors - Management fees have risen due to payments made for intermediary services related to restructuring [1] - Research and development expenses have increased as the company continues to invest in new product development and improve its R&D management system [1] Group 3: Other Income and Asset Management - The company has experienced a reduction in government subsidies related to daily operations, leading to decreased other income [1] - A comprehensive review of receivables and other assets has been conducted, resulting in the decision to provision for potential asset impairment losses, which has also contributed to increased impairment losses [1]
科源制药2025年净利同比预降35%至55%